Cystic Fibrosis in Focus

Host: Paul Doghramji, MD

Guest: Gregory S. Sawicki, MD, MPH

Even though there currently isn’t a cure for cystic fibrosis, there may finally be hope on the horizon for the more than 70,000 people around the world who are living with this debilitating disease. Joining Dr. Paul Dogramji to talk about the emerging treatment options for cystic fibrosis is Dr. Gregory Sawicki, Director at the Cystic Fibrosis Center and Assistant Professor of Pediatrics at Harvard Medical School.

Host: John J. Russell, MD

Guest: Suzanne Michel, MPH, RD, LDN

Approximately 85-90% of patients with Cystic Fibrosis suffer from pancreatic insufficiency since birth, which significantly complicates the disease and adversely affects both quality of life and life expectancy. Join Professor Suzanne Michele, registered dietitian, as she discusses supplemental enzymes and their role in the health of persons who have CF, the barriers to adherence with pancreatic enzyme replacement therapy, and how pancreatic enzyme replacement therapy is dosed in patients with CF.

Host: John J. Russell, MD

Guest: Patrick Flume, MD

Nontuberculous mycobacteria infection of the lung (a.k.a. NTM lung disease) is becoming increasingly common. In this activity, we are going to discuss how patients are evaluated and treated, as well as potential complications to be aware of in the management of NTM lung disease. Commercial Support:No commercial support has been provided for this activity.

Host: Barnett Mennen, MD

Guest: Peter J. Mogayzel, Jr, MD, PhD, MBA

This activity discusses the etiology of cystic fibrosis lung disease, the current clearance approaches and the role CFTR modulator therapy in the treatment of cystic fibrosis lung disease, and the relationship between lung function and nutritional status in cystic fibrosis.

Host: Barnett Mennen, MD

Guest: Denis Hadjiliadis, MD, MHS, PhD

Lung Transplantation is often considered for patients with cystic fibrosis. In this activity, we will discuss how patients are evaluated and listed, common complications, medications that are used, and survival after lung transplantation.

Host: Barnett Mennen, MD

Guest: Erin McElroy Barker, LCSW

Patients with cystic fibrosis and their families are at a higher risk for mental health issues which have been associated with other complications. In this activity, Ms. McElroy Barker will discuss how the CF community recognized the need for mental health services and the guidelines the CF Foundation recommends for screening patients.

Host: Jennifer Caudle, DO

Guest: Robert L. Zanni, MD, CPI

Airway clearance is the primary therapy for patients with cystic fibrosis. In this activity, Dr. Zanni will discuss the rationale for performing airway clearance, as well as current mechanical and pharmacologic choices for patients. He will also discuss airway clearance therapies that are making their way through the pipeline.

A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients. Flume PA, VanDevanter DR, Morgan EE, Dudley MN, Loutit JS, Bell SC, Kerem E, Fischer R, Smyth AR, Aaron SD, Conrad D, Geller DE,Elborn JS.

J Cyst Fibros. 2016 Jul;15(4):495-502. doi: 10.1016/j.jcf.2015.12.004. Epub 2016 Feb 4.

Abstract

RATIONALE:

For patients with cystic fibrosis (CF), the use of inhaled antibiotics has become standard of care to suppress chronic Pseudomonas airways infection. There are limited antibiotic options formulated and approved for inhaled use and antibiotic efficacies attenuate over time, making additional inhaled antibiotic classes desirable. APT-1026 (levofloxacin inhalation solution, LIS) is a fluoroquinolone in development for management of chronic P. aeruginosa airways infection in patients with CF.

OBJECTIVES:

To compare the safety and efficacy of a 28-day course of treatment with LIS 240mg or placebo BID in persons ≥12years old with CF and chronic P. aeruginosa infection.

METHODS:

A multinational, randomized (2:1), double-blinded study of LIS and placebo over 28days in CF patients ≥12years with chronic P. aeruginosa infection. Time to exacerbation was the primary endpoint. FEV1 (% predicted) and patient-reported …

Microbial colonization and lung function in adolescents with cystic fibrosis. Hector A, Kirn T, Ralhan A, Graepler-Mainka U, Berenbrinker S, Riethmueller J, Hogardt M, Wagner M, Pfleger A, Autenrieth I, Kappler M, Griese M, Eber E, Martus P, Hartl D.

J Cyst Fibros. 2016 May;15(3):340-9. doi: 10.1016/j.jcf.2016.01.004. Epub 2016 Feb 5.

Abstract

With intensified antibiotic therapy and longer survival, patients with cystic fibrosis (CF) are colonized with a more complex pattern ofbacteria and fungi. However, the clinical relevance of these emerging pathogens for lung function remains poorly defined. The aim ofthis study was to assess the association of bacterial and fungal colonization patterns with lung function in adolescent patients with CF. Microbial colonization patterns and lung function parameters were assessed in 770 adolescent European (German/Austrian) CF patients in a retrospective study (median follow-up time: 10years). Colonization with Pseudomonas aeruginosa and MRSA were most strongly associated with loss of lung function, while mainly colonization with Haemophilus influenzae was associated with preservedlung function. Aspergillus fumigatus was the only species that was associated with an increased risk for infection with P. aeruginosa.Microbial interaction analysis revealed three distinct microbial clusters within the longitudinal course of CF lung disease. …

A novel treatment of cystic fibrosis acting on-target: cysteamine plus epigallocatechin gallate for the autophagy-dependent rescue of class II-mutated CFTR.

Tosco A, De Gregorio F, Esposito S, De Stefano D, Sana I, Ferrari E, Sepe A, Salvadori L, Buonpensiero P, Di Pasqua A, Grassia R, Leone CA,Guido S, De Rosa G, Lusa S, Bona G, Stoll G, Maiuri MC, Mehta A, Kroemer G, Maiuri L, Raia V.

Cell Death Differ. 2016 Aug;23(8):1380-93. doi: 10.1038/cdd.2016.22. Epub 2016 Apr 1.

Abstract
We previously reported that the combination of two safe proteostasis regulators, cysteamine andepigallocatechin gallate (EGCG), can be used to improve deficient expression of the cystic fibrosistransmembrane conductance regulator (CFTR) in patients homozygous for the CFTR Phe508del mutation. Here we provide the proof-of-concept that this combination treatment restored CFTR function and reduced lung inflammation (P<0.001) in Phe508del/Phe508del or Phe508del/null-Cftr (but not in Cftr-null mice), provided that such mice were autophagy-competent. Primary nasal cells from patients bearing different class II CFTR mutations, either in homozygous or compound heterozygous form, responded to the treatment in vitro. We assessed individual responses to cysteamine plus EGCG in a single-centre, open-label phase-2 trial. The combination treatment decreased sweat chloride from baseline, increased both CFTR …